Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20292006 | 0.97 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HRH3CHRM4 | |
| SCHEMBL20291998 | 0.97 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HRH3CHRM4 | |
| SCHEMBL20292045 | 0.97 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2HRH3CHRM4 | |
| SCHEMBL23853843 | 0.89 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2HRH3CHRM4 | |
| SCHEMBL20291977 | 0.87 | TSHR (0.40) | NPC1RAB9ASMN1; SMN2ALDH1A1CYP3A4 | |
| SCHEMBL18382185 | 0.87 | CHRM4 (0.49) | NPC1RAB9ASMN1; SMN2HRH3CHRM4 | |
| SCHEMBL23849577 | 0.87 | CHRM4 (0.40) | NPC1RAB9ASMN1; SMN2HRH3CHRM4 | |
| SCHEMBL20291982 | 0.86 | HRH3 (0.34) | NPC1RAB9ASMN1; SMN2HRH3CHRM4 | |
| SCHEMBL18923661 | 0.86 | CYP1A2 (0.43) | NPC1RAB9ASMN1; SMN2CHRM4ALDH1A1 | |
| SCHEMBL16992538 | 0.86 | CYP1A2 (0.43) | NPC1RAB9ASMN1; SMN2CHRM4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102568-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. | HEPTARES THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | claimed |
| US-20170240530-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-08-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240530-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | NPC1 1913/4885RAB9A 943/4885SMN1; SMN2 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.